– UK, Cambridge – Isogenica are pleased to announce the appointment of Dr. Chris Ullman as CEO with effect from September 29th 2014, following the decision by Dr. Kevin Matthews to leave Isogenica to join a publicly listed polymer technology company.

Dr. Ullman has been with Isogenica since 2002 and was promoted into the CSO role in 2009. Over the last five years he has been instrumental in developing Isogenica’s strategy, taking the lead role in driving Isogenica’s technologies and has worked closely with Isogenica’s customers and partners.

“Dr. Ullman has worked closely with Dr. Matthews over the last five years and has been at the heart of delivering a fundamental change in the capability and direction of the business. I am sure that Chris will be successful in further developing Isogenica to provide technologies and technology capabilities that are valued by its pharma and biotech partners and academic collaborators,” said Jan-Olof Lundin, Chairman of Isogenica.

Note to Editors

Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technologies, CIS display and Colibra™, for the pharma and biotech industries. Founded in 2000, Isogenica is able to offer high quality proprietary and customised gene libraries and discovery services in order to shorten the lead time from target to bioactive lead candidate for biological therapeutic or diagnostic products

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.